Coulter Partners, the global experts in Executive Search and Leadership Development in Life Sciences, Health and Tech, announces the appointment of Dr. Hannah Musisi as Executive Director, based in London. Hannah will support our work in the Digital Health sector, working closely with Ian Coyne, Executive Director.
Targeted programme to identify and accelerate novel oncology innovations into commercially attractive assets; supported by unique insights from a collaboration of leading pharma, CROs, and subject matter experts in residence from across the global oncology R&D ecosystem.
The Medicines Manufacturing Innovation Centre – a unique collaboration led by technology innovation catalyst CPI alongside 24 partner organisations from pharma, government, business, and academia – opens in Glasgow, Scotland; The Centre’s ‘Grand Challenge’ business model follows the UK Life Sciences Strategy roadmap to accelerate innovation and is driving sustainable manufacturing processes to reduce the industry’s carbon footprint.
Funding from the Bill & Melinda Gates Foundation will build on preclinical data showing the potential of nanoparticle-formulated doggybone DNA to deliver strong antibody titres and strong T cell responses.
Brainomix to distribute Pixyl.Neuro.MS Software as a Service (SaaS) solution exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe. The emergence of disease-modifying drugs now offers more personalized treatment of multiple sclerosis, a neurological disorder that affects more than 2.3 million people worldwide. This has elevated the role of MRI in supporting both the diagnosis and ongoing disease monitoring and treatment response, opening the door for AI-powered solutions such as Pixyl’s Neuro.MS software to improve diagnosis and speed up treatment.
Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces the BASG (Bundesamt für Sicherheit im Gesundheitswesen) clearance of the Group’s Clinical Trial Application (CTA) for AT278, an ultra-rapid acting, ultra-concentrated (500 U/mL) insulin candidate, in Type 2 diabetic patients, the primary target population.
Through the combination of ACROBiosystems’ high-quality multi-pass transmembrane proteins and Carterra’s innovative LSA platform, large-scale comprehensive characterization of drug candidates using high-throughput surface plasmon resonance (HT-SPR) can be rapidly performed.